Frequently asked questions
The global fill finish pharmaceutical contract manufacturing market was valued at USD 9.5 Billion in 2022.
The fill finish pharmaceutical contract manufacturing market is expected to grow at a CAGR of 12.5% between 2023 and 2030, reaching USD 21.6 Billion in 2030.
Vials are the leading segment by Molecule type, holding over 30% share in value in 2022.
The small molecules segment governs the global demand for fill finish pharmaceutical contract manufacturing, holding a massive share of over 70% in 2022.
The biopharmaceutical companies’ equipment segment is expected to post the highest CAGR during the forecast period.
North America is fuelling the growth of the fill finish pharmaceutical contract manufacturing industry, with an over one-third share in 2022.
The top players include Boehringer Ingelheim, Catalent Inc, Recro Pharma, Inc., and Baxter’s BioPharma Solutions.
The major market drivers are increasing demand for complex drug formulations, growing biologics market, and focus on cost reduction and operational efficiency.
Major market restraints are stringent regulatory requirements, quality standards, and intellectual property concerns.
Increasing demand for personalized medicines, adoption of advanced packaging solutions, rising need for specialized primary containers, and growing market for orphan drugs and rare diseases.